EUVIMEDEUVIMED entdecken
Crossref

Is it Possible to Predict High-Risk Patients in Acute Pulmonary Embolism with Systemic Immune-Inflammation Index?

Murat DUYAN, Ali SARIDAŞ, Nafis VURAL

Eurasian Journal of Critical Care · 2022

DOI: 10.55994/ejcc.1193320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Critical Care, 2022. Verfasst von Murat DUYAN und 2 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: The authors declare no conflict of interest or any financial support..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute pulmonary embolism (APE) is a cardiovascular emergency that has a high morbidity and mortality probability. The aim of this study is to investigate the clinical value of the systemic immune inflammation index (SII) in predicting high-risk patients admitted to the emergency department with a diagnosis of Acute pulmonary embolism (APE). Materials and Methods: This clinical study, which was conducted according to a cross-sectional study design, included 193 patients diagnosed with APE who presented to the emergency department of a tertiary hospital. According to the guideline, patients with Pulmonary Embolism Severity Index (PESI) class III–V or sPESI ≥I were identified as high risk. ROC (Area Under the Curve) analysis was used to determine the cut-off in predicting high-risk APE.

Results

In our research, 71 of the patients had high-risk APE. In detecting high-risk APE, SII was found to have excellent diagnostic power (AUC: 0.84), while neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and monocyte to lymphocyte (MLR) were found to have acceptable diagnostic power (AUC: 0.76-0.78), red cell distribution width (RDW) to lymphocyte (RLR) was of fair diagnostic power (AUC: 0.68).

Conclusion

We have shown that SII can be a valuable and useful potential biomarker to identify high-risk patients in patients with APE. We also found that MLR and RLR are biomarkers that can be used to predict severe APE.

Förderung

  • The authors declare no conflict of interest or any financial support.

Zitieren

APA

DUYAN, M., SARIDAŞ, A., & VURAL, N. (2022). Is it Possible to Predict High-Risk Patients in Acute Pulmonary Embolism with Systemic Immune-Inflammation Index?. Eurasian Journal of Critical Care. https://doi.org/10.55994/ejcc.1193320

Vancouver

DUYAN M, SARIDAŞ A, VURAL N. Is it Possible to Predict High-Risk Patients in Acute Pulmonary Embolism with Systemic Immune-Inflammation Index?. Eurasian Journal of Critical Care. 2022. doi:10.55994/ejcc.1193320

BibTeX
@article{DUYAN2022,
  author = {DUYAN, Murat and SARIDAŞ, Ali and VURAL, Nafis},
  title = {Is it Possible to Predict High-Risk Patients in Acute Pulmonary Embolism with Systemic Immune-Inflammation Index?},
  journal = {Eurasian Journal of Critical Care},
  year = {2022},
  doi = {10.55994/ejcc.1193320}
}
Kostenlos starten →